Please ensure Javascript is enabled for purposes of website accessibility

A Foolish Take: The Best-Performing S&P 500 Stock This Year

By John Maxfield – Oct 23, 2017 at 12:00PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

This biotechnology specialist is soundly beating the broader market.

It has been a good year so far for stocks, with the S&P 500 up 15% since the beginning of 2017. But that's just an average of the 500 stocks on the large-cap index; some have done even better.

At the top is Vertex Pharmaceuticals (VRTX 0.33%). It is the best-performing stock on the S&P 500 this year, boasting gains of 110%.

A line chart comparing the performance of Vertex to the S&P 500.

Data source: YCharts.com. Chart by author.

Vertex is a global biotechnology company that specializes in treatments for cystic fibrosis, a genetic disease that affects the lungs and limits patients' ability to breathe.

The company sells two treatments: Kalydeco and Orkambi. What makes them unique is that they address the underlying cause of cystic fibrosis; other drugs on the market just treat the side effects.

Vertex's stock has climbed as the Food and Drug Administration (FDA) continues to expand the population of people approved to take Kalydeco as a treatment. Its original approval in 2012 was for cystic fibrosis patients with a specific mutation in the gene that causes the disease. At the end of 2014, Kalydeco won a second approval, followed by approval for another 10 mutations in 2015. Earlier this year, that was increased again to 33 mutations.

It is a promising trend not only for patients with cystic fibrosis, but also for shareholders of the Boston, Massachusetts-based company. And things could get better from here, as Vertex is seeking approval for additional treatments.

John Maxfield has no position in any of the stocks mentioned. The Motley Fool recommends Vertex Pharmaceuticals. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Vertex Pharmaceuticals Stock Quote
Vertex Pharmaceuticals
VRTX
$316.33 (0.33%) $1.03

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
351%
 
S&P 500 Returns
115%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 11/29/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.